TCRT — Alaunos Therapeutics Income Statement
0.000.00%
Last trade - 00:00- $9.51m
- $7.57m
- $0.01m
Annual income statement for Alaunos Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0.398 | 2.92 | 0.005 | 0.01 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 80.4 | 77.9 | 38 | 34.3 | 4.82 |
| Operating Profit | -80.4 | -77.5 | -35.1 | -34.3 | -4.81 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -80 | -78.8 | -37.7 | -35.1 | -4.68 |
| Net Income After Taxes | -80 | -78.8 | -37.7 | -35.1 | -4.68 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -80 | -78.8 | -37.7 | -35.1 | -4.68 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -80 | -78.8 | -37.7 | -35.1 | -4.68 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -57.2 | -52 | -26.2 | -18.4 | -2.92 |